Diagnosis and Treatment of Chronic Viral Hepatitis B and C: Doctrinary Approach

Husić-Selimović, Azra; Vukobrat-Bijedić, Zora; Bevanda, Milenko; Mesihović, Rusmir; Zerem, Enver; Ahmetagić, Sead; Trbojevic, S Ivana; Verhaz, Antonija; Kezić, Zdravka; Zildžić, Muharem; Bojanić, Janja; Petrovic, Jasminka; Stojic, Vildana; Ferhatović, Merdina; Ibrahimpasic, Nevzeta; Mrdjen, Visnja; Zivlak, Nera; Barac, Tatjana; Bebek-Ivanković, Helien; Čalkić, Lejla; Karin, Maja; Dobrovoljski, Aleksandar; Rajic, Romana; Skrbic, Milan; Babić, Nenad; Bevanda-Glibo, Daniela

doi:10.5455/medarh.2012.66.s56-s68

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic infection with hepatitis B virus represents a global health problem, with continuing new infections worldwide, being an important cause of liver disease, morbidity, and mortality (Husic-Selimovic et al, 2012). The goals of therapy in HBV infected patients are to limit or reverse progression of the disease through sustained suppression of HBV replication.…”

Section: Discussionmentioning

confidence: 99%

Use of ALLGIO Probe Assays for Detection of HBV Resistance to Adefovir in Patients with Chronic Hepatitis B, Kerman, Iran

Afshar

Mollaie²

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is contagious with transmissiobn vertically or horizontally by blood products and body secretions. Over 50% of Iranian carriers contracted the infection prenatally, making this the most likely route of transmission of HBV in Iran. To evaluate the resistance to adefovir (ADV) therapy in patients with chronic hepatitis B infection, a study was conducted on 70 patients (63 males and 7 females), who had received in first line lamivudine and second line adefovir. All were tested for the presence of hepatitis B surface antigen (HBsAg), hepatitis B envelope antigen (HBeAg), serum alanine amino transferase (ALT) level and HBV DNA load before and after treatment with ADV. In all samples, resistance to lamivudine and ADV was tested with real time PCR. Among seventy patients with chronic hepatitis B infection, 18 (25.7%) were resistant to LAM and 8 (11.4%) were resistant to ADV. Only one patient was negative for the presence of HBS-Ag (5.6%) and two were negative for HBe-Ag (11.1%). In this study we used a new method (ALLGIO probe assay) that has high sensitivity in detection of adefovir resistance mutants, which we recommend to other researchers. Mutant strains of the YMDD motif of HBV polymerase can be found in some patients under treatment with lamivudine and ADV. ADV has been demonstrated to be efficient in patients with lamivudine resistant HBV.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of ALLGIO Probe Assays for Detection of HBV Resistance to Adefovir in Patients with Chronic Hepatitis B, Kerman, Iran

Afshar

Mollaie²

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The current standard treatment of chronic hepatitis C in Bosnia and Herzegovina consists of the use of pegylated interferon alpha, subcutaneously, once a week, combination with ribavirin, daily (PEG-INF-α-2a+RBV). The treatment lasts between 48 or 24 weeks ( 2 ). Interferon therapy is associated with many psychiatric significant adverse effects (insomnia, tension, irritability, dispersion, forgetfulness), and the most prominent form is depressive symptomatology ( 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

The Effect of Combination Antiviral Therapy in the Treatment of Hepatitis C on the Occurrence of Depressive Disorder in Patients Treated for Hepatitis C in the Republic of Srpska

Banjac¹,

Zivlak-Radulovic²,

Miskovic³

2016

Med Arh

View full text Add to dashboard Cite

Background:The current standard treatment of chronic hepatitis C in Bosnia and Herzegovina consists of pegylated interferon alpha in combination with ribavirin. Interferon therapy has many psychiatric side effects, with depressive symptomatology being most prominent. The aim of the study was to establish the frequency and severity of depression in patients with chronic hepatitis C during two months of the aforementioned therapy.Subjects and Methods:The overall sample consisted of 46 subjects, divided into three subgroups, aged 18 to 65. The study population consisted of subjects treated for chronic hepatitis C (n = 15), subjects infected but not treated for chronic hepatitis C (n = 15), and healthy controls (n = 16). The assessment and level of depression were based on the Structural clinical interview (SCID), Montgomery-Asberg Depression Rating Scale and Zung Self-Rating Depression Scale. The assessments were conducted before interferon therapy (on the day 0), after 4 and 8 weeks of therapy.Results:Regarding its frequency, MADRS scoring showed that the number of depressed subjects receiving therapy increased after 8 weeks (46.7%). There was statistical significance between the subgroups after 4 and 8 weeks. Likewise, the ZUNG scale showed that the number of depressed subjects receiving therapy increased after 8 weeks (73.3%). There was statistical significance between the subgroups on the day 0, after 4 and 8 weeks.Conclusions:Depression was significantly more frequent in chronic hepatitis C subjects treated with interferon alpha in combination with ribavirin than in subjects in the group without therapy. Mild depression was most prevalent.

show abstract

Economic evaluation of HBV vaccination: A systematic review of recent publications (2000–2013)

Torre

Mannocci

Saulle

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Aim: To conduct a systematic review of the economic evaluations (EE) of HBV vaccination, taking also into account the studies published in the new millennium. Methods: An extensive scientific literature review was conducted using two electronic medical journal databases: Scopus and PubMed engines for published studies on EE of HBV vaccination. Results: 22 articles were reviewed, 9, 5 and 8 cost-effectiveness, cost-benefit and cost-utility analysis, respectively. Studies were mainly concerning EE of universal vaccination (UV), mostly with regards to low or low-medium income countries. For high income countries, EE were focused on the possible implementation of HBV vaccination in particular settings, such as diabetic, renal and other chronic conditions care, as well as infectious diseasesUV has usually a very good cost-effectiveness ratio (80%), ranging from cost-saving (China) or few Euro per LY/QALY gained (in Thailand, and Vietnam) to 630.00$/ QALY in USA (Asian and Pacific Islands) Moreover, EE of HBV vaccination are favorable in the infectious diseases field as well as for chronic conditions. In relation to diabetes the studies gave controversial results. Conclusion: This systematic review highlighted the importance of introducing HBV vaccination not only for infant UV program but also for other settings in which patients are people affected by communicable and non-communicable diseases.

show abstract

Diagnosis and Treatment of Chronic Viral Hepatitis B and C: Doctrinary Approach

Cited by 6 publications

References 0 publications

Use of ALLGIO Probe Assays for Detection of HBV Resistance to Adefovir in Patients with Chronic Hepatitis B, Kerman, Iran

Use of ALLGIO Probe Assays for Detection of HBV Resistance to Adefovir in Patients with Chronic Hepatitis B, Kerman, Iran

The Effect of Combination Antiviral Therapy in the Treatment of Hepatitis C on the Occurrence of Depressive Disorder in Patients Treated for Hepatitis C in the Republic of Srpska

Economic evaluation of HBV vaccination: A systematic review of recent publications (2000–2013)

Contact Info

Product

Resources

About